Aptamer Group Plc · LSE:APTA
Aptamer — H1 FY2023 Earnings Presentation
16 slides from Aptamer's earnings presentation, March 2023
Slide 1: Aptamer Group Interim Results Presentation
Aptamer Group Interim Results Presentation for 6 months to 31 Dec 2022
Slide 2: Disclaimer
DISCLAIMER Private and Confidential - for personal use only and not for distribution This presentation (“Presentation”) contains forward-looking statements, including in relation to the financial position and prospects of Aptamer Group plc (“Company”) and its group (“Group”). These forward-looking s
Slide 3: Management team
Management team Dr Arron Tolley Dr Rob Quinn CEO CFO (Joined 1 March 2023) • Co-founded Aptamer Group in 2008 • Experienced healthcare CFO, including • Globally-recognised technical & working with Silence Therapeutics commercial leader in aptamers • Also worked for GSK, BenevolentAI and • Delivered
Slide 4: Aptamer Group investment case
Aptamer Group investment case 01 02 Targeting $146bn affinity Proprietary high-throughput ligand market to meet automated platform for rapid demand for alternative ligand discovery and solutions development 03 04 Commercial momentum Fee-for-service contracts building and strong building foundations
Slide 5: Market demand for alternatives to antibodies
Market demand for alternatives to antibodies The $146bn affinity ligand market is well established, but has well-known problems that are addressable with aptamers Value creating differentiating characteristics of aptamer affinity ligands Broader target applicability Targets that are not possible wit
Slide 6: Affinity ligand technology market
Affinity ligand technology market • Target binding molecules are used in a wide range of applications in the life sciences • These binders are known as ‘affinity ligands' and represent a market worth >$US 145.7bn with CAGR c.11.3% • Historically, this market has been dominated by antibodies • More r
Slide 7: The Optimer platform
The Optimer® platform Partner Targets Applications Therapeutics • Therapeutic inhibitors & modulators Targeted delivery vehicles Toxins, Multiple Optimer® libraries • hormones as starting materials for each discovery 3 discovery processes Solutions/Bioprocessing tuned for target type to increase suc
Slide 8: USP: Automated high-throughput discovery platform
USP: Automated high-throughput discovery platform Tailored selection strategies, optimised for different target classes and applications, increases the potential for success in each Optimer discovery campaign. • Teams of specialists, with distinct processes to address different target types (protein
Slide 9: Investment for growth
Investment for growth Aptamer Group is accelerating growth and increasing value capacity over multiple verticals to deliver more solutions and higher value engagements Commercial expansion & Scale-up & automation service development Platform innovation New custom-fitted Expanded commercial £350k inv
Slide 10: Business units
Business units • Contract research services • Enabling Diagnostics • Enabling Therapeutics • Global research antibody market valued • Global diagnostic speciality antibodies • Global antibody therapeutic market at $13.1bn in 2021 market valued at $20.8bn in 2021 worth in excess of $126.7bn in 2021 •
Slide 11: HY23 operational and post-period highlights
HY23 operational and post-period highlights HY23 Operational Highlights Post-period highlights • Top 5 pharma company (Jul) • Follow-on contract to develop Optimer® binders as IHC reagents • Custom enzyme manufacturer (Jan) • Optimer® for monitoring enzyme manufacturing processes • Top 10 pharma com
Slide 12: Revenue model
Revenue model • Revenue model includes fee-for-service and licensing contracts to balance funding of development cost and speed to market, with opportunity for long term, high value deals 1. Fee-for-service provides faster access to revenues and funds ongoing platform development without exposure to
Slide 13: Financial performance H1 Financial Year 2023
Financial performance H1 Financial Year 2023 • Group revenue of £1.0m, second half weighted • Net cash outflow from operations of £2.9m • Gross profit margin improvement • £1.8m investment in new laboratory, equipment and office space • Admin expenses increased significantly due to • £0.5m R&D tax c
Slide 14: Outlook for the Full Year 2023
Outlook for the Full Year 2023 • The first half of the financial year has seen new contracts signed across all business units for Aptamer Group, with further contract signing post-period end and visibility of a significant number of potential orders already in place for the second half of the year.
Slide 15: Aptamer Group summary
Aptamer Group summary 01 02 Targeting $146bn affinity Proprietary high-throughput ligand market to meet automated platform for rapid demand for alternative ligand discovery and solutions development 03 04 Commercial momentum Fee-for-service contracts building and strong building foundations and pipe
Slide 16: Thank you
Thank you W: aptamergroup.com E: [email protected] T: +44 (0) 1904 217404